Axumin PET/CT Scans Lead to Treatment Changes in Most Recurring Prostate Cancer Patients, Phase 3 Trial Shows

Axumin PET/CT Scans Lead to Treatment Changes in Most Recurring Prostate Cancer Patients, Phase 3 Trial Shows
In men suspected of recurring prostate cancer, imaging with Axumin (18F-fluciclovine) was able to accurately reveal sites of recurrence, which led to a change of treatment plans for 59 percent of the patients, topline results from the Phase 3 LOCATE trial show. Trial findings were recently presented in a poster, “Impact of positron emission tomography with 18F-fluciclovine on management of patients with suspected recurrence of prostate cancer: results from the LOCATE trial,” at the
Subscribe or to access all post and page content.